HemoSonics LLC, a medical device company focused on acute bleeding management, today announced that its Quantra® Hemostasis System for Obstetric Procedures is one of the top three finalists in the ...

OrsoBio, a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, today announced positive topline results from a Phase 2a proof-of-concept study ...

Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...

Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its ...

Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for ...

Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to Hold.

NEW ORLEANS, LA—Adding the factor XIa inhibitor asundexian (Bayer) to antiplatelet therapy tops antiplatelet therapy alone ...

Among adults with acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) with planned ...

US FDA grants priority review status to Pfizer’s Hympavzi sBLA to treat two haemophilia A or B patient populations with significant medical need: New York Monday, February 9, 20 ...

Pfizer Inc. (NYSE: PFE)today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's ...